Highlights
1 patentProfile claimed by owner
About
Novel Molecular Treatment for Dry Age-related Macular Degeneration
OphtiMed Rx is developing a novel molecular therapy for dry age-related macular degeneration (AMD), a common eye disease leading to blindness. The company’s treatment protects retinal cells from senescence (cellular aging) and can halt the progression of dry AMD.
OphtiMed Rx’s therapy is designed to prevent the loss of vision and independence caused by dry AMD, providing an enormous benefit to patients.
Identity
| Name | OphtiMed Rx |
|---|---|
| Slug | ophtimed-rx |
| Type / kind | startup |
| Source _id | ZoIGWCqqMOhz2FwFydFbsSqV4nRfhXApPo0ueZNANrIHx7VPX02jGn |
Status
| Status | active |
|---|---|
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ city | Afula |
| HQ address | Afula, Israel |
Web & social
| Website | https://www.galilofek.com/ophtimedrx/ |
|---|---|
| https://www.linkedin.com/company/78752697 |
Classifications
Primary sector Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsMolecules
Target customers
Healthcare & Life SciencesHealthcareLaboratories
Business models
B2B
Tags
pharmaceuticalspharma-companiesdrug-discoveryprivate-investorsophthalmologyinvestorseye-diseasesdrug-development
Funding
| Total raised | $1.3M |
|---|---|
| Current stage | Seed |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}